The hardest part of pharmaceutical sales is not finding another data point. It is deciding what to do at 8:17 on a Tuesday morning. A physician opened an email but ignored the last two. A new clinical paper landed overnight. The brand team wants one message emphasized, the medical team has another conversation in progress, and a rep has twelve possible calls. Aktana’s software sits in that crowded moment and offers a recommendation: contact this person, through this channel, with this context, now.
That sounds like ordinary sales automation until the constraints come into view. Life sciences companies operate across countries, products, regulations, specialties, sales territories, medical firewalls and digital platforms. Their healthcare-professional data can be rich but scattered. Their campaign plan may be decided months before the market changes. Their customer, meanwhile, experiences every visit, message and webinar as one relationship. Aktana’s job is to help the company behave the same way.
01 / The productA to-do list with a memory
Aktana calls its core the Contextual Intelligence Engine. The phrase is clinical; the behavior is familiar. It acts like a well-briefed colleague who remembers previous interactions, knows the brand rules, notices a change in channel availability and explains why a particular action belongs at the top of the list. The engine ingests customer profiles, engagement history, market data, predictive models, strategy and operational limits. It then ranks the possible actions across field and digital channels.
A recommendation can be a rep visit, an approved email, a content choice, a handoff or a decision to hold back. That last option matters. Omnichannel programs often confuse coordination with volume. If a physician just read a clinical update, the intelligent move may be to suppress a near-identical message and queue a complementary conversation instead. Personalization is partly the art of not repeating yourself.
Signals arrive
CRM activity, preferences, content response, market events and field feedback.
Rules apply
Brand strategy, compliance, capacity and channel constraints narrow the field.
Actions rank
The engine chooses timing, channel, message and the next useful move.
Humans answer
Acceptance, rejection and customer response become fuel for the next decision.
The representative does not disappear from this loop. Suggestions arrive with context, and users can accept, reject or respond. The system learns from that feedback while the user retains judgment. This is a practical distinction in a regulated market: a black-box score may be clever, but an explainable prompt has a better chance of earning trust and being used.
“AI should empower your teams, augment their capabilities, align objectives to execution, and elevate human decision-making rather than replace it.”John Vitalie, Aktana CEO, 2025
02 / The customerThe people behind the prescription pad
Aktana sells to pharmaceutical, biotechnology and medical-device companies, not to physicians or patients directly. Its users include sales representatives, brand managers, commercial operations teams, marketers, medical-science liaisons and analytics groups. Public programs have featured teams from Sanofi, Eli Lilly, Roche and Organon; Aktana says its broader footprint spans more than 350 brands and over half of the world’s top 20 drugmakers.
These customers are buying coordination. A brand leader wants strategy to survive the trip from headquarters to the field. A representative wants a short, credible briefing rather than another dashboard. Marketing wants to know whether its next email complements the field conversation. Medical affairs needs context while maintaining the required separation from commercial activity. The common problem is that each team can make a locally reasonable decision that produces a globally awkward customer experience.
03 / The differenceVertical AI, down to the plumbing
Aktana is not a replacement CRM. It is an intelligence layer that connects to systems such as Veeva, Salesforce, Adobe and marketing platforms. That positioning has become more valuable as life sciences companies face expensive CRM transitions. In late 2024 the company introduced its Action Agent as a field assistant designed to preserve useful guidance across those migrations. The pitch is continuity: change the system of record without discarding the decision logic sitting above it.
The company’s deeper advantage is accumulated specificity. Aktana has spent years learning how brand priorities become business rules, how a rep evaluates a suggestion, how medical and commercial teams share context without collapsing their boundaries, and how deployments differ across markets. A general-purpose model can summarize a call. It does not arrive knowing the organizational compromises that determine whether the next call should happen.
Competitors approach the same budget from several directions: Veeva, IQVIA and Salesforce own major workflow platforms; Axtria, ZS and Indegene bring analytics and commercial expertise; internal data-science teams can build custom models. Aktana’s answer has been openness and focus. Its API-first architecture accepts outside data and models, while its own optimization layer concentrates on the decision and the workflow around it.
04 / The businessSoftware sold with sleeves rolled up
Aktana is enterprise SaaS with a substantial services component. Historical investor material described licensing by representative and brand. A large rollout also requires integration, use-case design, business-rule configuration, model tuning, change management and ongoing measurement. In this corner of enterprise software, the product is not finished when the code runs; it is finished when teams change what they do.
That makes the sales cycle longer and the customer relationship stickier. It also explains Aktana’s partner ecosystem. Veeva and Salesforce connections put recommendations into familiar work. Adobe links field orchestration with digital personalization. Cantab Pi brought predictive analytics and millions of HCP profiles. Real Chemistry connected social and claims signals. The platform becomes more useful as it coordinates investments the customer has already made.
The company’s product line expanded with the same logic. Contextual Intelligence 360 broadened the engine into enterprise orchestration. Field and Omnichannel Orchestrators divided the problem by workflow. Strategy Suite added planning tools, including a hub for KPIs, a generative-AI tactic planner and a simulator for testing choices before deployment. Aktana for MedTech and Copilot Mobile carried guidance into device accounts, medical education and mobile field work.
The clever recommendation is only half a product. The other half is getting it into the right workflow before the moment passes.
05 / The turnFrom next best action to one joined-up journey
In January 2026, PharmaForceIQ acquired Aktana for an undisclosed amount. The buyer brought digital orchestration; Aktana brought an established field next-best-action engine and a larger international footprint. Together they described an “optichannel-in-a-box” system that connects brand strategy, digital media and field execution, with a proposed launch window as short as six to eight weeks.
The phrase “optichannel” is revealing. Omnichannel promises a presence across every channel. Optichannel asks which channel deserves the next interaction. That is closer to Aktana’s original character: not more activity, but a better choice. The acquisition thesis is that a field recommendation and a digital journey become more useful when both draw from the same memory and measure the same outcome.
Integration will be the real test. Enterprise software acquisitions can produce a wider menu without producing a simpler meal. PharmaForceIQ must connect the platforms while preserving the CRM flexibility, explanations and human feedback that made Aktana credible. Customers will care less about the combined feature list than whether a brand rule set at headquarters appears, correctly and promptly, in the next customer interaction.
06 / The lessonThe unglamorous craft of useful AI
Aktana’s history began before today’s agentic-AI vocabulary. The company was once called IncentAlign, then chose a name made from “actionable” and “analytics.” It moved from sales suggestions to contextual intelligence, omnichannel coordination, strategy simulation and agents. The labels changed faster than the underlying job: convert an unruly supply of information into a decision a person can use.
That is also what makes the company instructive. Its market is narrow, its deployments are hands-on, and its AI must coexist with old systems and firm boundaries. None of that makes for a frictionless product demo. It does create a defensible kind of expertise. The model matters, but so do the connector, the rule, the explanation, the feedback button and the consultant who knows why a technically sensible recommendation will land badly in one country.
For a pharmaceutical company, the payoff is not a futuristic conversation with a machine. It is a more coherent conversation with a doctor. A rep walks in better prepared. A marketer avoids sending the redundant follow-up. A medical team sees enough context to be relevant. Strategy adjusts while there is still time to matter. Aktana’s most interesting claim is therefore modest: the next action can be made a little less accidental.